Relmada Therapeutics Inc (OTCMKTS:RLMD) appointed Lisa Nolan, Ph.D. as senior VP of business development. In the new role, Dr. Nolan will look after the business development and alliance operations across the company. She has been in the healthcare segment for more than twenty years and has served on various roles including marketing and clinical research, strategic planning and business development. Prior to joining Relmada, she served as managing director of Nolex Advisors LLC. In this role, she looked after the business development and licensing operations for a number of private and public companies.
The expert speaks
Sergio Traversa, the CEO of Relmada, said that the management is very pleased to have Nolan joining the company as senior VP of business development. As a senior level executive with an outstanding deal sheet, she brings broad functional experience and strong leadership to the company. She will play an important role in all the company’s measures to maximize the opportunities for the chronic pain therapy lead product candidates.
Dr. Nolan served as chief business executive with Topigen Pharmaceuticals a Biopharma firm focused on unique respiratory therapeutics, and played a key role in the sale of Topigen to Pharmaxis Ltd in 2010. Before that she was associated with Skyepharma PLC, a specialty Pharma firm focused on pioneering drug delivery technologies. Working with Skyepharma she led several partnering deals with US and international firms.
Dr. Nolan said that she is looking forward to joining Relmada at such an exciting phase for the company. With a strong product pipeline in clinical stages, there is an opportunity to leverage her experience in strategic marketing and business development to have an immediate impact at the performance of the company. In last trading session, the stock price of Relmada declined 3.83% to close the trading session at $2.26 on share volume of 200, 046.